Evidence map›Paper›PMID 39721590›Full record

Trial reportBritish journal of haematology2025

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Etti Broide, Emmanuel Benayoun, Jacob M Rowe, Yishai Ofran

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chezi GanzelHematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.ORCID https://orcid.org/0000-0002-1722-4807
Avraham FrischDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Ofir WolachInstitute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yakir MosheDepartment of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Baher KrayemDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Neta DorHematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Etti BroideFlow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.
Emmanuel BenayounFlow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.
Jacob M RoweHematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Yishai OfranHematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.ORCID https://orcid.org/0000-0002-5521-1337

Funding

Jazz Pharmaceuticals P21589
6 · The paper itself

Abstract

This pilot study evaluated CPX-351 in adults with newly diagnosed, favourable-intermediate risk, FLT3-ITD-negative AML. Twenty patients received CPX-351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow-based minimal residual disease (MRD) negativity post-induction. The 18-month leukaemia-free and overall survival estimates were 80% and 95% respectively. Adding GO appeared safe without prolonged cytopenias. Subclinical cardiotoxicity was observed in 25% of patients. The study demonstrated CPX-351's feasibility, with response and MRD-negativity rates comparable to standard '7 + 3' induction.

Indexed as

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteAdultAgedAminoglycosidesAntibodies, Monoclonal, HumanizedCytarabineDaunorubicinFemaleGemtuzumabHumansInduction ChemotherapyMaleMiddle AgedNeoplasm, ResidualAminoglycosidesAntibodies, Monoclonal, HumanizedCPX-351CytarabineDaunorubicinFLT3 protein, humanfms-Like Tyrosine Kinase 3GemtuzumabAMLcardiotoxicityCPX‐351gemtuzumab ozogamicinMRDvyxeos

Identifiers

PMID39721590
PMCPMC11829133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.